CN113710239A - 视黄酸受体相关孤儿受体γ(RORγ)依赖性癌症的治疗 - Google Patents

视黄酸受体相关孤儿受体γ(RORγ)依赖性癌症的治疗 Download PDF

Info

Publication number
CN113710239A
CN113710239A CN202080028000.6A CN202080028000A CN113710239A CN 113710239 A CN113710239 A CN 113710239A CN 202080028000 A CN202080028000 A CN 202080028000A CN 113710239 A CN113710239 A CN 113710239A
Authority
CN
China
Prior art keywords
cancer
cells
ror
tumor
jte
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080028000.6A
Other languages
English (en)
Chinese (zh)
Inventor
丹妮莎·雷亚
尼基·莱特尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California, San Diego
Original Assignee
University of California, San Diego
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California, San Diego filed Critical University of California, San Diego
Publication of CN113710239A publication Critical patent/CN113710239A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN202080028000.6A 2019-02-20 2020-02-20 视黄酸受体相关孤儿受体γ(RORγ)依赖性癌症的治疗 Pending CN113710239A (zh)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201962808231P 2019-02-20 2019-02-20
US62/808,231 2019-02-20
US201962881890P 2019-08-01 2019-08-01
US62/881,890 2019-08-01
US201962897202P 2019-09-06 2019-09-06
US62/897,202 2019-09-06
US201962903595P 2019-09-20 2019-09-20
US62/903,595 2019-09-20
US202062959607P 2020-01-10 2020-01-10
US62/959,607 2020-01-10
PCT/US2020/019118 WO2020172467A1 (en) 2019-02-20 2020-02-20 Treatment for retinoic acid receptor-related orphan receptor ɣ (rorɣ)-dependent cancers

Publications (1)

Publication Number Publication Date
CN113710239A true CN113710239A (zh) 2021-11-26

Family

ID=72144161

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080028000.6A Pending CN113710239A (zh) 2019-02-20 2020-02-20 视黄酸受体相关孤儿受体γ(RORγ)依赖性癌症的治疗

Country Status (5)

Country Link
US (1) US20220202811A1 (cg-RX-API-DMAC7.html)
EP (1) EP3927329A4 (cg-RX-API-DMAC7.html)
JP (1) JP2022520859A (cg-RX-API-DMAC7.html)
CN (1) CN113710239A (cg-RX-API-DMAC7.html)
WO (1) WO2020172467A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021149786A1 (en) * 2020-01-24 2021-07-29 Japan Tobacco Inc. Methods of treating cancer using dihydropyrimidin-2-one compounds
AU2024267864A1 (en) * 2023-05-09 2025-11-06 11949098 Canada Inc. Inverse agonists of rar related orphan receptors (rors)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9629910B2 (en) * 2011-03-22 2017-04-25 The Brigham And Women's Hospital, Inc. Use of Th9 cells and IL-9 for the treatment of melanoma
WO2012158784A2 (en) * 2011-05-16 2012-11-22 Theodore Mark Kamenecka Modulators of the nuclear hormone receptor ror
US9359315B2 (en) * 2013-09-10 2016-06-07 Arrien Pharmaceuticals Llc Substituted 2,3-dihydro-1H-inden-1-one retinoic acid-related orphan nuclear receptor antagonists for treating multiple sclerosis
WO2015083130A1 (en) * 2013-12-06 2015-06-11 Aurigene Discovery Technologies Limited Fused pyridine and pyrimidine derivatives as ror gamma modulators
SI3207043T1 (sl) * 2014-10-14 2019-04-30 Vitae Pharmaceuticals, Inc. Dihidropirolopiridinovi inhibitorji za ROR-gama
CN107614062A (zh) * 2015-03-12 2018-01-19 加利福尼亚大学董事会 用RORγ抑制剂治疗癌症的方法
KR102702236B1 (ko) * 2015-05-15 2024-09-04 오리진 온콜로지 리미티드 Ror 감마 조절제로서의 치환된 테트라하이드로퀴놀리논 화합물
US20240245633A1 (en) * 2015-11-04 2024-07-25 University Of Florida Research Foundation, Incorporated ROR Gamma Agonists as Enhancers of Protective Immunity
WO2017127442A1 (en) * 2016-01-18 2017-07-27 The Regents Of The University Of California Methods for treating cancer with rorgamma inhibitors

Also Published As

Publication number Publication date
EP3927329A4 (en) 2022-11-23
WO2020172467A1 (en) 2020-08-27
EP3927329A1 (en) 2021-12-29
US20220202811A1 (en) 2022-06-30
JP2022520859A (ja) 2022-04-01

Similar Documents

Publication Publication Date Title
Chen et al. Oncogenic collagen I homotrimers from cancer cells bind to α3β1 integrin and impact tumor microbiome and immunity to promote pancreatic cancer
Broz et al. Metabolic targeting of cancer associated fibroblasts overcomes T-cell exclusion and chemoresistance in soft-tissue sarcomas
Lytle et al. A multiscale map of the stem cell state in pancreatic adenocarcinoma
Bai et al. CDK4/6 inhibition triggers ICAM1-driven immune response and sensitizes LKB1 mutant lung cancer to immunotherapy
Liu et al. Tumors exploit FTO-mediated regulation of glycolytic metabolism to evade immune surveillance
Morel et al. EZH2 inhibition activates a dsRNA–STING–interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer
Leruste et al. Clonally expanded T cells reveal immunogenicity of rhabdoid tumors
Kumar et al. LncRNA Malat1 suppresses pyroptosis and T cell-mediated killing of incipient metastatic cells
Schwartzman et al. Suppressors and activators of JAK-STAT signaling at diagnosis and relapse of acute lymphoblastic leukemia in Down syndrome
Chia et al. HMGA1 induces FGF19 to drive pancreatic carcinogenesis and stroma formation
Lehrich et al. Precision targeting of β-catenin induces tumor reprogramming and immunity in hepatocellular cancers
JP2021040648A (ja) 腫瘍細胞による免疫抑制を低下させるための方法および組成物
Fang et al. The potential regulatory roles of circular RNAs in tumor immunology and immunotherapy
Zhu et al. Targeting the chromatin effector Pygo2 promotes cytotoxic T cell responses and overcomes immunotherapy resistance in prostate cancer
Portale et al. C/EBPβ-dependent autophagy inhibition hinders NK cell function in cancer
US20250043270A1 (en) A method of treating acute myeloid leukemia
Sonzogni et al. Reporters to mark and eliminate basal or luminal epithelial cells in culture and in vivo
Enukashvily et al. Pericentromeric satellite lncRNAs are induced in cancer-associated fibroblasts and regulate their functions in lung tumorigenesis
Mondal et al. Brd7 loss reawakens dormant metastasis initiating cells in lung by forging an immunosuppressive niche
Gau et al. Vascular endothelial profilin-1 drives a protumorigenic tumor microenvironment and tumor progression in renal cancer
Belenki et al. Senescence-associated lineage-aberrant plasticity evokes T-cell-mediated tumor control
Zhang et al. ZEB1 promotes chemoimmunotherapy resistance in pancreatic cancer models by downregulating chromatin acetylation of CXCL16
Wang et al. hsa_circ0021347 as a Potential target regulated by B7‐H3 in modulating the malignant characteristics of osteosarcoma
Portelinha et al. SETD1B mutations confer apoptosis resistance and BCL2 independence in B cell lymphoma
Mirgayazova et al. Impact of TP53 mutations on the efficacy of CAR-T cell therapy in cancer

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination